Jump to Main Content
The Emerging Role of <span style="font-variant: small-caps">l</span>-Glutamine in Cardiovascular Health and Disease
- Durante, William
- Nutrients 2019 v.11 no.9
- DNA, adenosine triphosphate, anti-inflammatory activity, antioxidants, apoptosis, arginine, diabetes, extracellular matrix, glucose, glutamate dehydrogenase, glutamine, glutathione, heart failure, heat shock proteins, heme oxygenase (biliverdin-producing), hyperlipidemia, hypertension, lipids, models, nitric oxide, obesity, patients, physiology, pulmonary artery, risk factors, sickle cell anemia, therapeutics, tricarboxylic acid cycle
- Emerging evidence indicates that l-glutamine (Gln) plays a fundamental role in cardiovascular physiology and pathology. By serving as a substrate for the synthesis of DNA, ATP, proteins, and lipids, Gln drives critical processes in vascular cells, including proliferation, migration, apoptosis, senescence, and extracellular matrix deposition. Furthermore, Gln exerts potent antioxidant and anti-inflammatory effects in the circulation by inducing the expression of heme oxygenase-1, heat shock proteins, and glutathione. Gln also promotes cardiovascular health by serving as an l-arginine precursor to optimize nitric oxide synthesis. Importantly, Gln mitigates numerous risk factors for cardiovascular disease, such as hypertension, hyperlipidemia, glucose intolerance, obesity, and diabetes. Many studies demonstrate that Gln supplementation protects against cardiometabolic disease, ischemia-reperfusion injury, sickle cell disease, cardiac injury by inimical stimuli, and may be beneficial in patients with heart failure. However, excessive shunting of Gln to the Krebs cycle can precipitate aberrant angiogenic responses and the development of pulmonary arterial hypertension. In these instances, therapeutic targeting of the enzymes involved in glutaminolysis such as glutaminase-1, Gln synthetase, glutamate dehydrogenase, and amino acid transaminase has shown promise in preclinical models. Future translation studies employing Gln delivery approaches and/or glutaminolysis inhibitors will determine the success of targeting Gln in cardiovascular disease.